<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04940273</url>
  </required_header>
  <id_info>
    <org_study_id>KY2021-001</org_study_id>
    <nct_id>NCT04940273</nct_id>
  </id_info>
  <brief_title>Drug Intervention of Spontaneous Hyperventilation in Patients With Aneurysmal Subarachnoid Hemorrhage</brief_title>
  <official_title>Intervention of Spontaneous Hyperventilation in Patients With Aneurysmal Subarachnoid Hemorrhage: the Feasibility of Drug Therapy and Its Impact on Cerebral Blood Flow</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Capital Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Capital Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although spontaneous hyperventilation patients with aneurysmal subarachnoid hemorrhage&#xD;
      closely associated with poor outcomes, the standard therapy remains unavailable. Remifentanil&#xD;
      has the pharmacological characterization of respiratory inhibition, mainly prolonging the&#xD;
      expiratory time and decreasing the respiratory rate while preserving the respiratory drive.&#xD;
      The investigators hypothesis that spontaneous hyperventilation could be corrected by&#xD;
      titrating the dose of remifentanil and cerebral blood flow will augment during this process.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evidence has shown a high incidence of spontaneous hyperventilation in patients with&#xD;
      aneurysmal subarachnoid hemorrhage (aSAH), which is associated with poor outcomes. It's well&#xD;
      established that the hypocapnia caused by hyperventilation leads to cerebral&#xD;
      vasoconstriction, reduces the cerebral blood flow, and decreases the cerebral blood volume&#xD;
      and intracranial pressure consequently. However, persistent cerebral vascular constriction&#xD;
      increases the risk of cerebral ischemia; therefore, maintaining a partial pressure of&#xD;
      arterial carbon dioxide (PaCO2) in the range of 35-40mmHg is recommended to minimize the&#xD;
      hazard hypocapnia.&#xD;
&#xD;
      There's still no standard method to deal with spontaneous hyperventilation. Based on the&#xD;
      pharmacology and clinical experience, remifentanil seems to be an ideal choice since it could&#xD;
      inhibit the respiratory rate in a dose-dependent fashion. As one of the most used&#xD;
      short-acting opioids, remifentanil could prolong the expiratory time, meanwhile not&#xD;
      influencing the inspiratory time and respiratory drive, consequently decreasing respiratory&#xD;
      rate and maintaining the tidal volume.&#xD;
&#xD;
      In this exploratory physiology study, the investigators will test the hypothesis that&#xD;
      spontaneous hyperventilation could be suppressed by titrating the dose of remifentanil and&#xD;
      could be realized as the target of PaCO2. The investigators will determine the optimal amount&#xD;
      of remifentanil, which fulfills the criteria of efficacy and safety, and evaluate its effect&#xD;
      on the cerebral blood flow velocity of both the middle cerebral artery and internal carotid&#xD;
      artery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Explore the effective and safe dose of remifentanil to correct spontaneous hyperventilation in patients with aSAH</measure>
    <time_frame>The PaCO2 (mmHg) at baseline and 30 minutes following each infusion rate adjustment (0.02、0.04、0.06、0.08μg/kg/min)</time_frame>
    <description>The differences of partial pressure of carbon dioxide (PaCO2; mmHg) between the respective points (baseline and 30 minutes following each infusion rate adjustment of remifentanil) were recorded to determine the change of PaCO2 (mmHg).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To explore the effect of remifentanil on the cerebral blood flow in patients with aSAH at the different dose</measure>
    <time_frame>The MFV at baseline and 30 minutes following each infusion rate adjustment (0.02、0.04、0.06、0.08μg/kg/min)</time_frame>
    <description>The differences of mean cerebral flow velocity (MFV) of middle cerebral artery and Internal carotid artery between baseline and 30 minutes following each infusion rate adjustment of remifentanil were recorded to determine the change of cerebral blood flow.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hyperventilation</condition>
  <condition>Aneurysmal Subarachnoid Hemorrhage</condition>
  <condition>Cerebral Blood Flow</condition>
  <arm_group>
    <arm_group_label>remifentanil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Continuous infusion of remifentanil at a dose of 0.02、0.04、0.06、0.08 ug/kg/min for 30 minutes in sequence.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil Injection [Ultiva]</intervention_name>
    <description>Continuous infusion of remifentanil at a dose of 0.02、0.04、0.06、0.08 ug/kg/min for 30 minutes in sequence.</description>
    <arm_group_label>remifentanil</arm_group_label>
    <other_name>remifentanil hydrochloride for injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aneurysmal subarachnoid hemorrhage, after craniotomy or clipping&#xD;
&#xD;
          -  Arterial blood gas satisfy with PaCO2&lt;35mmHg and pH&gt;7.45&#xD;
&#xD;
          -  Presence of an endotracheal tube&#xD;
&#xD;
          -  Assisted ventilation mode,CPAP/PSV&#xD;
&#xD;
          -  ICP monitoring&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Chronic obstructive pulmonary disease&#xD;
&#xD;
          -  Allergy to opioids&#xD;
&#xD;
          -  Clinically relevant hepatic or renal failure&#xD;
&#xD;
          -  Hemodynamic instability&#xD;
&#xD;
          -  TCD windows cannot detect cerebral blood flow&#xD;
&#xD;
          -  Refuse to participate the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhou Jian-Xin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Capital Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhou Jian-Xin, MD</last_name>
    <phone>010-59976518</phone>
    <email>zhoujx.cn@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Hong-Liang, MD</last_name>
    <phone>15910678616</phone>
    <email>arnold_lhl@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ICU, Beijing Tiantan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian-Xin Zhou, MD</last_name>
      <email>zhoujx.cn@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>June 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2021</study_first_posted>
  <last_update_submitted>June 23, 2021</last_update_submitted>
  <last_update_submitted_qc>June 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Capital Medical University</investigator_affiliation>
    <investigator_full_name>Jian-Xin Zhou</investigator_full_name>
    <investigator_title>department head</investigator_title>
  </responsible_party>
  <keyword>spontaneous hyperventilation</keyword>
  <keyword>aneurysmal subarachnoid hemorrhage</keyword>
  <keyword>cerebral blood flow</keyword>
  <keyword>remifentanil</keyword>
  <keyword>partial pressure of carbon dioxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperventilation</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

